Sanofi has agreed to acquire Ablynx, a Ghent, Belgium-based biopharmaceutical company focused on therapeutic proteins based on single-domain antibody fragments, for approximately EUR 3.9 billion ($4.8 billion). Sanofi says the move continues its focus on technologies addressing multiple disease targets with single multi-specific molecules. Read More

Pfizer plans to invest approximately $5 billion in capital projects in the US over the next five years, which includes strengthening its manufacturing presence. AbbVie plans to invest approximately $2.5 billion in capital projects in the US over the next five years and is evaluating additional expansion of its US facilities. The companies made the announcement as part of their 2017 financial results. Read More

During his State of the Union address, President Trump noted several policy issues relating to healthcare, including lowering prescription drug prices and improving access to investigational drugs. Read More

The European Medicines Agency (EMA) Executive Director Guido Rasi commented on the agency’s relocation of the EMA from London to Amsterdam following the UK’s decision to exit the European Union (i.e., Brexit). Rasi calls it the “single biggest challenge the EMA has ever had since its establishment” and provided an update of the move. Read More

Seattle Genetics, a biopharmaceutical company focused on oncology, has agreed to acquire Cascadian Therapeutics, another biopharmaceutical company focused on oncology, for $614 million. Read More

Amneal Pharmaceuticals, a generic-drug manufacturer, plans to expand its manufacturing plant in Long Island, New York for solid dose and softgel products. The proposed expansion follows Amneal’s October 2017 announcement of a merger with Impax Laboratories, a specialty pharmaceutical company focused on controlled-release and specialty generics. Read More

An advisory committee of the European Medicines Agency has recommended approval of a biosimilar to Sanofi’s, Lantus (insulin glargine) from Mylan and Biocon, a Bangalore, India-based pharmaceutical company. Lantus had 2016 sales of EUR 5.71 billion ($6.54 billion). Read More

Celgene Executive Chairman Bob Hugin plans to retire after 19 years of service and will step down from Celgene’s Board of Directors, effective February 5, 2018. Current CEO Mark Alles has been appointed to the additional role of chairman of the board of directors. Read More

As part of its plan to address opioid addiction, the FDA has released a revised blueprint for opioid prescriber education, outlined possible changes in requirements for opioid packaging, and held a hearing to seek feedback on its oversight of opioids. Read More

Offering a new business model in healthcare, JPMorgan Chase & Co., Berkshire Hathaway, and Amazon have partnered to form a new healthcare company to provide healthcare for their US employees with the aim of improving employee satisfaction and reducing costs. Read More